N
3.86
-0.04 (-1.03%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | NovaBridge Biosciences | - | - |
AIStockmoo Score
-1.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.25 |
|
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Exome Asset Management Llc | 30 Sep 2025 | 1,439,604 |
| Edbi Pte Ltd | 31 Dec 2024 | 222,136 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |